HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma

Author:

Jacobson Caron1,Kopp Nadja1,Layer Jacob V.1,Redd Robert A.2,Tschuri Sebastian345,Haebe Sarah345,van Bodegom Diederik1,Bird Liat1,Christie Amanda L.16,Christodoulou Alexandra1,Saur Amy6,Tivey Trevor1,Zapf Stefanie7,Bararia Deepak345,Zimber-Strobl Ursula7,Rodig Scott J.8,Weigert Oliver345,Weinstock David M.19

Affiliation:

1. Department of Medical Oncology and

2. Department of Biostatistics & Computational Biology, Dana-Farber Cancer Institute, Boston, MA;

3. Department of Medicine III, Laboratory for Experimental Leukemia and Lymphoma Research, Ludwig-Maximilians University, Munich, Germany;

4. German Cancer Consortium, Heidelberg, Germany;

5. German Cancer Research Center, Heidelberg, Germany;

6. Lurie Family Imaging Center, Dana-Farber Cancer Institute, Boston, MA;

7. Department of Gene Vectors, Helmholtz Zentrum München, German Research Center for Environment and Health, Munich, Germany;

8. Department of Pathology, Brigham and Women’s Hospital, Boston, MA; and

9. Broad Institute, Harvard University and Massachusetts Institute of Technology, Cambridge, MA

Abstract

Key Points Inhibition of HSP90 targets multiple dependences in mantle cell lymphoma. Clinically available HSP90 inhibitors overcome ibrutinib resistance in vitro and in vivo.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Cited by 37 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3